Bodyport

Digital therapeutics for chronic heart conditions

San Francisco, California, United States

About Bodyport

Bodyport focuses on helping individuals manage chronic conditions, especially heart failure. The company offers at-home devices that use a biomarker platform to noninvasively measure various hemodynamic biomarkers related to heart health. This technology enables patients and their healthcare teams to monitor changes in heart health more effectively, which can lead to fewer hospital visits and better health outcomes. Bodyport stands out from competitors by providing actionable health insights through its proprietary platform, which not only sells devices but may also offer subscription services for continuous health monitoring. The main goal of Bodyport is to empower patients to take control of their health and improve their quality of life.

San Francisco, CaliforniaHeadquarters
2015Year Founded
$15.4MTotal Funding
SERIES_ACompany Stage
Biotechnology, HealthcareIndustries
11-50Employees

Risks

Increased competition from companies like Eko Devices with similar cardiac monitoring solutions.
Potential regulatory challenges as FDA tightens guidelines on digital health devices.
Data privacy concerns due to stricter legislation like the California Privacy Rights Act.

Differentiation

Bodyport offers noninvasive hemodynamic biomarker measurement for heart failure management.
The company integrates a sophisticated biomarker platform into user-friendly, at-home devices.
Bodyport's partnership with Geisinger enhances its credibility and market reach.

Upsides

The rise of remote patient monitoring technologies presents a significant market opportunity.
FDA guidance encourages innovation in noninvasive monitoring, aligning with Bodyport's offerings.
Demand for subscription-based health monitoring services is increasing, boosting potential revenue.

Funding